July 21, 2024
all-antibody

Immune Factors That Influence The Persistence of Antiphospholipid

Epidemiological, scientific and immune elements that affect the persistence of antiphospholipid antibodies in leprosy.

Antiphospholipid antibodies (aPL) are described in people with leprosy with out the scientific options of antiphospholipid antibody syndrome (APS), a situation involving thromboembolic phenomena. We’ve got described the persistence of those antibodies for over 5 years in sufferers with leprosy after particular remedy.To find out whether or not epidemiological, scientific and immunological elements performed a job within the long-term persistence of aPL antibodies in leprosy sufferers after multidrug remedy (MDT) had completed.

METHODS

The research pattern consisted of 38 sufferers with a analysis of leprosy being adopted up on the Dermatology and Venereology Outpatient Division on the Alfredo da Matta Basis (FUAM) in Manaus, AM. ELISA was used to detect anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. Sufferers have been reassessed on common of 5 years after particular remedy for the illness (MDT) had been accomplished.

RESULTS

Persistence of aPL antibodies among the many 38 leprosy sufferers was 84% (32/38), and all had the IgM isotype. Imply age was 48.1 ± 15.9 years, and 23 (72.0%) have been male. The lepromatous kind (LL) of leprosy was the commonest (n = 16, 50%). Reactional episodes have been noticed in three sufferers (9.4%). Eighteen (47.37%) have been nonetheless taking treatment (prednisone and/or thalidomide).

 

Imply IgM ranges have been 64 U/mL for aCL and 62 U/mL for anti-β2GPI. Within the multivariate binary logistic regression the next variables confirmed a big affiliation: age (p = 0.045, OR = 0.91 and CI 95% 0.82-0.98), LL scientific presention (p = 0.034; OR = 0.02 and CI 95% = 0.0-0.76) and bacterial index (p = 0.044; OR = 2.74 and CI 95% = 1.03-7.33). We didn’t discover affiliation between prednisone or thalidomide doses and positivity for aPL (p = 0.504 and p = 0.670, respectively).

 

No variations within the variables vascular thrombosis, being pregnant morbidity, diabetes, smoking and alcoholism have been discovered between aPL-positive and aPL-negative sufferers.Persistence of positivity for aPL antibodies was influenced by age, scientific presentation and bacterial index. Nonetheless, additional research are wanted to elucidate the explanation for this persistence, the position performed by aPL antibodies within the illness and the B cell lineages liable for era of those antibodies.

all-antibody
all-antibody

human anti-human IL-4 mAb (52)

E4A09D04-52 50ug
EUR 255
Description: Available in various conjugation types.

human anti-human IL-4 mAb (C1)

E4A09D04-C1 50ug
EUR 255
Description: Available in various conjugation types.

Rat Anti Human Interleukin-4, IL-4, unconjugated

MBS396740-01mg 0.1mg
EUR 260

Rat Anti Human Interleukin-4, IL-4, unconjugated

MBS396740-5x01mg 5x0.1mg
EUR 1015

Rat Anti Human Interleukin-4, IL-4, unconjugated

MBS396742-01mg 0.1mg
EUR 260

Rat Anti Human Interleukin-4, IL-4, unconjugated

MBS396742-5x01mg 5x0.1mg
EUR 1015

Rat Anti Human Interleukin-4, IL-4, unconjugated

MBS396744-01mg 0.1mg
EUR 260

Rat Anti Human Interleukin-4, IL-4, unconjugated

MBS396744-5x01mg 5x0.1mg
EUR 1015

Anti-Human IL-4

GWB-BIG229 500ug Ask for price

Anti-Human IL-4

MBS550674-01mg 0.1mg
EUR 260

Anti-Human IL-4

MBS550674-02mg 0.2mg
EUR 335

Anti-Human IL-4

MBS550686-01mg 0.1mg
EUR 260

Anti-Human IL-4

MBS550686-02mg 0.2mg
EUR 335

Anti‐Human IL‐17A

E2790213 100ul
EUR 225
Description: Available in various conjugation types.

IL-4, Human

E34M006H 5 μg
EUR 155

Human IL-4

GWB-CB2917 0.01 mg Ask for price

Human IL-4

gAP-0227 1mg
EUR 450

Human IL-4

MBS691496-0002mg 0.002mg
EUR 225

Human IL-4

MBS691496-5x0002mg 5x0.002mg
EUR 725

Human IL-4

MBS691811-005mg 0.05mg
EUR 555

Human IL-4

MBS691811-5x005mg 5x0.05mg
EUR 2205

Human IL-4

MBS691915-001mg 0.01mg
EUR 265

Human IL-4

MBS691915-5x001mg 5x0.01mg
EUR 890

IL-4, Human

MBS8575163-0005mg 0.005mg
EUR 245

IL-4, Human

MBS8575163-5x0005mg 5x0.005mg
EUR 940

Anti-Human IL-4 Antibody

101-M05 500 µg
EUR 246.75
Description: Interleukin 4 (IL-4) is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. It was initially identified as a B cell differentiation factor (BCDF), as well as a B cell stimulatory factor (BSF1). IL-4 has since been shown to have multiple biological effects on hematopoietic and non-hematopoietic cells, including B and T cells, monocytes, macrophages, mast cells, myeloid and erythroid progenitors, fibroblasts, and endothelial cells. Rat, mouse and human IL-4 are species-specific in their activities.

Anti-Human IL-4 Antibody

101-M508 100 µg
EUR 399
Description: Interleukin 4 (IL-4) is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. It was initially identified as a B cell differentiation factor (BCDF), as well as a B cell stimulatory factor (BSF1). IL-4 has since been shown to have multiple biological effects on hematopoietic and non-hematopoietic cells, including B and T cells, monocytes, macrophages, mast cells, myeloid and erythroid progenitors, fibroblasts, and endothelial cells. Rat, mouse and human IL-4 are species-specific in their activities.

Anti-Human IL-4 Antibody

102-P34 100 µg
EUR 245.7
Description: Interleukin 4 (IL-4) is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. It was initially identified as a B cell differentiation factor (BCDF), as well as a B cell stimulatory factor (BSF1). IL-4 has since been shown to have multiple biological effects on hematopoietic and non-hematopoietic cells, including B and T cells, monocytes, macrophages, mast cells, myeloid and erythroid progenitors, fibroblasts, and endothelial cells. Rat, mouse and human IL-4 are species-specific in their activities.

Anti-human IL-4 antibody

STJ15100045 250 µg
EUR 403.2
Description: This monoclonal antibody enables sensitive and specific detection of human IL-4 in immunoassays such as ELISA and ELISpot.

Anti-human IL-4 antibody

STJ15100046 250 µg
EUR 440.4
Description: This monoclonal antibody enables sensitive and specific detection of human IL-4 in immunoassays such as ELISA and ELISpot.

Human Interleukin-4 (IL-4) Antibody

32184-05111 150 ug
EUR 215

Anti-Human IL-4 PE

MBS697227-100Tests 100Tests
EUR 360

Anti-Human IL-4 PE

MBS697227-25Tests 25Tests
EUR 215

Anti-Human IL-4 PE

MBS697227-5x100Tests 5x100Tests
EUR 1580

Anti-Human IL-4 PE

MBS697234-100Tests 100Tests
EUR 335

Anti-Human IL-4 PE

MBS697234-25Tests 25Tests
EUR 185

Anti-Human IL-4 PE

MBS697234-5x100Tests 5x100Tests
EUR 1475

Anti-Human IL-4 APC

MBS697235-100Tests 100Tests
EUR 320

Anti-Human IL-4 APC

MBS697235-25Tests 25Tests
EUR 185

Anti-Human IL-4 APC

MBS697235-5x100Tests 5x100Tests
EUR 1395

Mouse Anti-Human IL-4

MBS690917-05mg 0.5mg
EUR 525

Mouse Anti-Human IL-4

MBS690917-5x05mg 5x0.5mg
EUR 2080

Human Interleukin-4 (IL-4)

1-CSB-EP011659HU
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Interleukin-4(IL-4) expressed in E.coli

Interleukin-4 (IL-4) Human

GWB-2A39E4 0.01 mg Ask for price

IL-4, Interleukin-4, human

RC212-15 5ug
EUR 125.26

human anti-human IL-2 mAb

E409C12-h100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human IL-5 mAb

E409C14-h100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human IL-8 mAb

E409C16-h100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human IL-5 mAb

E4A09D05 50ug
EUR 255
Description: Available in various conjugation types.

Human anti-Human IL-2 mAb

MBS8576800-005mg 0.05mg
EUR 325

Human anti-Human IL-2 mAb

MBS8576800-01mLAF405L 0.1mL(AF405L)
EUR 565

Human anti-Human IL-2 mAb

MBS8576800-01mLAF405S 0.1mL(AF405S)
EUR 565

Human anti-Human IL-2 mAb

MBS8576800-01mLAF610 0.1mL(AF610)
EUR 565

Human anti-Human IL-2 mAb

MBS8576800-01mLAF635 0.1mL(AF635)
EUR 565

Human anti-Human IL-5 mAb

MBS8576804-005mg 0.05mg
EUR 325

Human anti-Human IL-5 mAb

MBS8576804-01mLAF405L 0.1mL(AF405L)
EUR 565

Human anti-Human IL-5 mAb

MBS8576804-01mLAF405S 0.1mL(AF405S)
EUR 565

Human anti-Human IL-5 mAb

MBS8576804-01mLAF610 0.1mL(AF610)
EUR 565

Human anti-Human IL-5 mAb

MBS8576804-01mLAF635 0.1mL(AF635)
EUR 565

Human anti-Human IL-8 mAb

MBS8576808-005mg 0.05mg
EUR 325

Human anti-Human IL-8 mAb

MBS8576808-01mLAF405L 0.1mL(AF405L)
EUR 565

Human anti-Human IL-8 mAb

MBS8576808-01mLAF405S 0.1mL(AF405S)
EUR 565

Human anti-Human IL-8 mAb

MBS8576808-01mLAF610 0.1mL(AF610)
EUR 565

Human anti-Human IL-8 mAb

MBS8576808-01mLAF635 0.1mL(AF635)
EUR 565

human anti-human IL-1β mAb

E409C11-h100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human IL-10 mAb

E409C17-h100 100μL
EUR 395
Description: Available in various conjugation types.

Human anti-Human IL-10 mAb

MBS8576810-005mg 0.05mg
EUR 325

Human anti-Human IL-10 mAb

MBS8576810-01mLAF405L 0.1mL(AF405L)
EUR 565

Human anti-Human IL-10 mAb

MBS8576810-01mLAF405S 0.1mL(AF405S)
EUR 565

Human anti-Human IL-10 mAb

MBS8576810-01mLAF610 0.1mL(AF610)
EUR 565

Human anti-Human IL-10 mAb

MBS8576810-01mLAF635 0.1mL(AF635)
EUR 565

Human anti-Human IL-1beta mAb

MBS8576798-005mg 0.05mg
EUR 325

Human anti-Human IL-1beta mAb

MBS8576798-01mLAF405L 0.1mL(AF405L)
EUR 565

Dissecting the molecular foundation of excessive viscosity of monospecific and bispecific IgG antibodies.

Some antibodies exhibit elevated viscosity at excessive concentrations, making them poorly fitted to therapeutic functions requiring administration by injection akin to subcutaneous or ocular supply. Right here we studied an anti-IL-13/IL-17 bispecific IgG4 antibody, which has anomalously excessive viscosity in comparison with its mum or dad monospecific antibodies.

 

  • The viscosity of the bispecific IgG4 in answer was decreased by solely ~30% within the presence of NaCl, suggesting electrostatic interactions are inadequate to completely clarify the drivers of viscosity. Intriguingly, addition of arginine-HCl diminished the viscosity of the bispecific IgG4 by ~50% to its mum or dad IgG degree.
  • These information counsel that past electrostatics, further varieties of interactions akin to cation-π and/or π-π might contribute to excessive viscosity extra considerably than beforehand understood. Molecular dynamics simulations of antibody fragments within the blended answer of free arginine and specific water have been performed to establish hotspots concerned in self-interactions.
  • Uncovered floor fragrant amino acids displayed an elevated variety of contacts with arginine. Mutagenesis of the vast majority of fragrant residues pinpointed by molecular dynamics simulations successfully decreased the answer’s viscosity when examined experimentally.
  • This mutational methodology to scale back the viscosity of a bispecific antibody was prolonged to a monospecific anti-GCGR IgG1 antibody with elevated viscosity. In all circumstances, level mutants have been readily recognized that each diminished viscosity and retained antigen-binding affinity.
  • These research show a brand new method to mitigate excessive viscosity of some antibodies by mutagenesis of surface-exposed fragrant residues on complementarity-determining areas that will facilitate some scientific functions.

Mouse Monoclonal anti-human PlGF

hAP-0010 100ug
EUR 250

Mouse PlGF

MBS691520-0002mg 0.002mg
EUR 265

Mouse PlGF

MBS691520-5x0002mg 5x0.002mg
EUR 890

Mouse PlGF

MBS692108-0005mg 0.005mg
EUR 350

Mouse PlGF

MBS692108-5x0005mg 5x0.005mg
EUR 1275

Mouse PlGF

MBS692180-002mg 0.02mg
EUR 625

Mouse PlGF

MBS692180-5x002mg 5x0.02mg
EUR 2510

Mouse Monoclonal anti-Human PlGF Antibody

xAP-0457 100ug
EUR 280

Anti-Mouse PlGF Antibody

103-M03 100 µg
EUR 399
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF-2 has been identified. Mouse PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic P lGF antibodies are being investigated to inhibit tumor growth and angiogenesis.

Anti-Mouse PlGF Antibody

103-PA04AG 50 µg
EUR 157.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Anti-Mouse PlGF Antibody

103-PA04S 100 µg
EUR 126
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Anti-Mouse PlGF Antibody

MBS4158465-01mg 0.1mg
EUR 1255

Anti-Mouse PlGF Antibody

MBS4158465-5x01mg 5x0.1mg
EUR 5390

Rabbit Anti-Mouse PlGF

103-PA04 100ug
EUR 240

Anti-Human PGF/PlGF/PLGF Nanobody

MBS1568114-01mg 0.1mg
EUR 405

Anti-Human PGF/PlGF/PLGF Nanobody

MBS1568114-5x01mg 5x0.1mg
EUR 1520

Mouse PLGF ELISA Kit

EMP0025 96Tests
EUR 625.2

Mouse PlGF Rabbit pAb

A24547 20μL
EUR 262.15

PLGF (PGF) (PlGF-1/2) mouse monoclonal antibody, clone 178/G10, Purified

DM3525 100 µg Ask for price

Mouse PlGF-2 ELISA Kit

E16ME0045 96T
EUR 833.33

Mouse PlGF-2 ELISA Kit

MBS8291429-5x96Tests 5x96Tests
EUR 2755

Mouse PlGF-2 ELISA Kit

MBS8291429-96Tests 96Tests
EUR 620

Mouse PlGF Recombinant Protein

M30-019 5 µg
EUR 136.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Mouse PlGF Recombinant Protein

M30-019S 2 µg
EUR 73.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF-1, PlGF-2 and PlGF-3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF-2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF-2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Mouse PlGF Recombinant Protein

M30-020 20 µg
EUR 313.95
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

PLGF (Mouse, monoclonal, antagonistic)

mP1002r-m 100ug
EUR 467.5

PLGF (PGF) (PlGF-1/2) mouse monoclonal antibody, clone 178/G10, Biotin, Purified

DM3525B 50 µg Ask for price

Rat Monoclonal anti-mouse PlGF

mAP-0010 100ug
EUR 250

Mouse PLGF-2 PicoKine ELISA Kit

EK0863 96 wells
EUR 510
Description: For Quantitative Detection of mouse PLGF-2 in cell culture supernates, serum and plasma (heparin, EDTA).

Mouse PLGF-2 PicoKine ELISA Kit

MBS1751078-5x96StripWells 5x96-Strip-Wells
EUR 2755

Mouse PLGF-2 PicoKine ELISA Kit

MBS1751078-96StripWells 96-Strip-Wells
EUR 600

PLGF (PGF) mouse monoclonal antibody, clone PLGF94, Purified

AM50307PU-S 100 µg Ask for price

PLGF (PGF) mouse monoclonal antibody, clone PLGF94, Purified

AM50307PU-T 20 µg Ask for price

Recombinant Mouse PLGF/PGF Protein

MBS9144052-002mg 0.02mg
EUR 235

Recombinant Mouse PLGF/PGF Protein

MBS9144052-005mg 0.05mg
EUR 320

Recombinant Mouse PLGF/PGF Protein

MBS9144052-01mg 0.1mg
EUR 460

Recombinant Mouse PLGF/PGF Protein

MBS9144052-5x01mg 5x0.1mg
EUR 1900

Purified recombinant Mouse PLGF protein

MBS5308876-001mg 0.01mg
EUR 380

Purified recombinant Mouse PLGF protein

MBS5308876-5x001mg 5x0.01mg
EUR 1660

Mouse PLGF / PGF Protein, His Tag

PGF-M52H0 50ug
EUR 3327.7
Description: Mouse PLGF, His Tag (PGF-M52H0) is expressed from human 293 cells (HEK293). It contains AA Val 19 - Pro 158 (Accession # P49764-1).

Anti-Rat PlGF Antibody

104-PA04AG 50 µg
EUR 157.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Anti-Rat PlGF Antibody

104-PA04S 100 µg
EUR 126
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis.

Rabbit anti PlGF (human)

102-PA04AG 50ug
EUR 240

Rabbit anti PlGF (human)

102-PA04S 100ug
EUR 240

Rabbit Anti-Rat PlGF

104-PA04 100ug
EUR 240

RABBIT ANTI HUMAN PLGF

MBS222860-01mg 0.1mg
EUR 660

RABBIT ANTI HUMAN PLGF

MBS222860-5x01mg 5x0.1mg
EUR 2795

Anti-Human PlGF Antibody

101-M03 100 µg
EUR 378
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M67 100 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M69 100 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-MBi67 50 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

102-P248 100 µg
EUR 245.7
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

MBS4158489-01mg 0.1mg
EUR 920

Anti-Human PlGF Antibody

MBS4158489-5x01mg 5x0.1mg
EUR 3880

Anti-Human PlGF-2 Antibody

101-M65 100 µg
EUR 246.75
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF-2 Antibody

101-M65A 100 µg
EUR 246.75
Description: Placenta Growth Factor-2 (PlGF-2), a 22 kDa protein consisting of 152 amino acid residues is produced as a homodimer. PlGF is a polypeptide growth factor and a member of the platelet-derived growth factor family but more related to vascular endothelial growth factor (VEGF). PlGF acts only as a weak mitogen for those cell types possessing receptors for binding (e.g. vascular endothelial cells). At least one high-affinity receptor for PlGF (FLT-1 or VEGF-R1) has been demonstrated in different primary cell types (e.g. human umbilical vein endothelial cells and monocytes). In addition to its action as a weak mitogen it is also a chemoattractant for monocytes and endothelial cells. Three different proteins are generated by differential splicing of the human PlGF gene: PlGF-1 (131aa native chain), PlGF-2 (152aa) and PlGF-3 (203aa). All 3 mitogens are secretable proteins, but PlGF-2 can bind to heparin with high affinity. PlGF is apparently a homodimer, but preparations of PlGF show some heterogeneity on SDS gels depending of the varying degrees of glycosylation. All dimeric forms possess similar biological activities. Heterodimers between VEGF and PlGF are mitogenic for endothelial cells and have strong angiogenic activity in vivo (e.g. in the CAM assay or in the cornea pocket assay). Different cells and tissues (e.g. placenta) express PlGF-1 and PlGF-2 at different rates. A much related protein of PlGF is VEGF with about 53% homology and VEGF-B with similar biological activities.

OKRC01283-96W - PLGF-2 ELISA Kit (Mouse)

OKRC01283-96W 96Wells
EUR 525

Mouse PLGF/PGF HEK293 Overexpression Lysate

MBS8116397-03mg 0.3mg
EUR 280

Mouse PLGF/PGF HEK293 Overexpression Lysate

MBS8116397-5x03mg 5x0.3mg
EUR 1205

Mouse PLGF/PGF HEK293 Overexpression Lysate

MBS8116398-03mg 0.3mg
EUR 280

Mouse PLGF/PGF HEK293 Overexpression Lysate

MBS8116398-5x03mg 5x0.3mg
EUR 1205

Placenta Growth Factor (PLGF) Polyclonal Antibody (Mouse)

4-PAA114Mu01
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Mouse Placenta Growth Factor (PLGF)

Mouse Placenta Growth Factor (PLGF) Protein

20-abx068553
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Placenta Growth Factor (PLGF) Protein

abx068553-20g 20 µg
EUR 562.5

Mouse Placenta Growth Factor (PLGF) Protein

abx068553-5g 5 µg
EUR 287.5

PLGF(PLGF93) Antibody

BNC810093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

Leave a Reply

Your email address will not be published. Required fields are marked *